Sponsor:
iLeukon Therapeutics, Inc.
Code:
NCT07452224
Conditions
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
ILKN421H
Pembrolizumab
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-22. This information was provided to ClinicalTrials.gov by iLeukon Therapeutics, Inc. on 2026-07-10.